Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 9/20 | 0.43 |
| ▸ | JAK3 | P52333 | 8/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763243 | 1.00 | CCNA2 (0.46) | CCNA2CDK2JAK2JAK3EGLN2 | |
| SCHEMBL5762626 | 0.88 | CCNA2 (0.43) | CCNA2CDK2JAK2JAK3EGLN2 | |
| SCHEMBL5762630 | 0.88 | CCNA2 (0.43) | CCNA2CDK2JAK2JAK3EGLN2 | |
| SCHEMBL5761161 | 0.88 | JAK2 (0.41) | CCNA2CDK2JAK2JAK3EGLN2 | |
| SCHEMBL5761156 | 0.88 | JAK2 (0.41) | CCNA2CDK2JAK2JAK3EGLN2 | |
| SCHEMBL5762610 | 0.83 | GBA1 (0.42) | CCNA2CDK2JAK2JAK1USP30 | |
| SCHEMBL5762607 | 0.83 | GBA1 (0.42) | CCNA2CDK2JAK2JAK1USP30 | |
| SCHEMBL5763208 | 0.82 | CCNA2 (0.44) | CCNA2CDK2JAK2JAK3EGLN2 | |
| SCHEMBL5763213 | 0.82 | CCNA2 (0.44) | CCNA2CDK2JAK2JAK3EGLN2 | |
| SCHEMBL5761901 | 0.78 | CYP2D6 (0.40) | JAK2JAK3KCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458683-B1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7012077-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186984-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | CCNA2 1854/4885CDK2 2536/4885JAK2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.